On­ly 1 of 25 can­cer drug de­vel­op­ers fair­ly in­clud­ed mi­nor­i­ty pa­tients over five-year win­dow, BMJ analy­sis finds

New clin­i­cal tri­al di­ver­si­ty plans, which FDA will soon ex­plain fur­ther, were fea­tured in the gov­ern­ment spend­ing pack­age that Pres­i­dent Joe Biden signed late last week and are com­ing at a time when they’re very much need­ed, ac­cord­ing to a new analy­sis pub­lished in the BMJ to­day.

Of the 25 com­pa­nies re­viewed for the new di­ver­si­ty rank­ings, Unit­ed Ther­a­peu­tics was the on­ly one with a per­fect fair in­clu­sion score of 100, but sev­en oth­ers — Puma Biotech­nol­o­gy, Sanofi, Take­da, Am­gen, Bris­tol My­ers Squibb, Eli Lil­ly, and Mer­ck KGaA — re­ceived a score in the top quar­tile on clin­i­cal tri­al di­ver­si­ty per­for­mance, ac­cord­ing to the analy­sis from Stan­ford, Yale and Bioethics In­ter­na­tion­al re­searchers, which was sup­port­ed by a grant from the Su­san G. Komen Foun­da­tion.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN